About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: CPRX
- Previous Close: $1.10
- 50 Day Moving Average: $1.15
- 200 Day Moving Average: $1.10
- 52-Week Range: $82,870,000.00 - $0.51
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.07
- P/E Growth: 0.00
- Market Cap: $91.16M
- Outstanding Shares: 82,870,000
- Beta: 2.26
- Return on Equity: -43.03%
- Return on Assets: -40.38%
Companies Related to Catalyst Pharmaceuticals:
- Current Ratio: 22.64%
- Quick Ratio: 22.64%
What is Catalyst Pharmaceuticals' stock symbol?
Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."
Where is Catalyst Pharmaceuticals' stock going? Where will Catalyst Pharmaceuticals' stock price be in 2017?
3 equities research analysts have issued 12 month price targets for Catalyst Pharmaceuticals' stock. Their forecasts range from $2.50 to $4.00. On average, they expect Catalyst Pharmaceuticals' stock price to reach $3.25 in the next year.
When will Catalyst Pharmaceuticals announce their earnings?
Catalyst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.
Who owns Catalyst Pharmaceuticals stock?
Catalyst Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Broadfin Capital LLC (9.90%) and Kingdon Capital Management L.L.C. (0.91%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, David D Muth, Donald A Denkhaus, M Douglas Winship, Patrick J Mcenany, Philip H Coelho and Steve Miller.
Who bought Catalyst Pharmaceuticals stock? Who is buying Catalyst Pharmaceuticals stock?
Catalyst Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Kingdon Capital Management L.L.C.. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, David D Muth, Donald A Denkhaus, Patrick J Mcenany, Philip H Coelho and Steve Miller.
How do I buy Catalyst Pharmaceuticals stock?
Shares of Catalyst Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Catalyst Pharmaceuticals stock cost?
One share of Catalyst Pharmaceuticals stock can currently be purchased for approximately $1.10.